OBJECTIVE: To investigate the physical and chemical compatibility of pentoxifylline (PTX) with a wide range of parenteral medications used in the neonatal intensive care setting. DESIGN: PTX and drug solutions were combined in glass phials and inspected visually for physical incompatibility. The chemical compatibility was evaluated on the basis of PTX concentrations. RESULTS: Precipitation, colour change or turbidity was not visible in any of the test mixtures, indicating no observed physical incompatibility or apparent risk of blockage in narrow-bore intravenous tubing. The PTX concentration was approximately 2.5% and 4.5% lower when combined with dopamine and amoxicillin, respectively. The PTX concentration ratios for all other combinatio...
: Objectives Physicochemical incompatibilities between intravenous drugs are a recurrent problem in ...
Sildenafil, a phosphodiesterase type-5 inhibitor, is used for the treatment of infants with pulmonar...
Sildenafil, a phosphodiesterase type-5 inhibitor, is used for the treatment of infants with pulmonar...
Patients in paediatric intensive care units (PICU) often receive numerous medications by the parente...
There is a lack of compatibility data for intravenous therapy to neonatal intensive care unit (NICU)...
Objective: To evaluate the visual compatibility of a standard total parenteral nutrition solution (S...
Objectives: The main objective was to investigate Y-site compatibility of intravenous drugs with one...
Both stability and compatibility of parenteral nutrition solutions (PNS) with drug products are majo...
Many pediatric intensive care patients require numerous specialized intravenous (IV) medications at ...
The purpose of this study was to determine the physical compatibility and chemical stability of nore...
OBJECTIVE: To determine the physical and chemical compatibilities of ciprofloxacin lactate infusion ...
The purpose of this study was to determine the physical compatibility and chemical stability of nore...
Preterm neonates require parenteral nutrition (PN) in addition to intravenous drug therapy. Due to l...
Parenteral antiepileptic drugs are frequently used in critically ill patients for seizure control th...
OBJECTIVE: Aminophylline and ceftazidime are sometimes used concurrently in patients with respirator...
: Objectives Physicochemical incompatibilities between intravenous drugs are a recurrent problem in ...
Sildenafil, a phosphodiesterase type-5 inhibitor, is used for the treatment of infants with pulmonar...
Sildenafil, a phosphodiesterase type-5 inhibitor, is used for the treatment of infants with pulmonar...
Patients in paediatric intensive care units (PICU) often receive numerous medications by the parente...
There is a lack of compatibility data for intravenous therapy to neonatal intensive care unit (NICU)...
Objective: To evaluate the visual compatibility of a standard total parenteral nutrition solution (S...
Objectives: The main objective was to investigate Y-site compatibility of intravenous drugs with one...
Both stability and compatibility of parenteral nutrition solutions (PNS) with drug products are majo...
Many pediatric intensive care patients require numerous specialized intravenous (IV) medications at ...
The purpose of this study was to determine the physical compatibility and chemical stability of nore...
OBJECTIVE: To determine the physical and chemical compatibilities of ciprofloxacin lactate infusion ...
The purpose of this study was to determine the physical compatibility and chemical stability of nore...
Preterm neonates require parenteral nutrition (PN) in addition to intravenous drug therapy. Due to l...
Parenteral antiepileptic drugs are frequently used in critically ill patients for seizure control th...
OBJECTIVE: Aminophylline and ceftazidime are sometimes used concurrently in patients with respirator...
: Objectives Physicochemical incompatibilities between intravenous drugs are a recurrent problem in ...
Sildenafil, a phosphodiesterase type-5 inhibitor, is used for the treatment of infants with pulmonar...
Sildenafil, a phosphodiesterase type-5 inhibitor, is used for the treatment of infants with pulmonar...